Motley Fool
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?
📊
AI Sentiment
Positive
6/10
- Home
- TEVA
as of 12-15-2025 11:16am EST
$30.01
+$0.24
+0.81%
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Chart Type:
Time Range:
| Founded: | 1901 | Country: | Israel |
| Employees: | N/A | City: | TEL AVIV |
| Market Cap: | 30.2B | IPO Year: | N/A |
| Target Price: | $29.78 | AVG Volume (30 days): | 10.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.46 - $30.20 | Next Earning Date: | 01-28-2026 |
| Revenue: | $16,776,000,000 | Revenue Growth: | 0.02% |
| Revenue Growth (this year): | 4.74% | Revenue Growth (next year): | 0.48% |
AI-Powered TEVA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 74.84%
74.84%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Teva Pharmaceutical Industries Limited News
TEVA Breaking Stock News: Dive into TEVA Ticker-Specific Updates for Smart Investing
Simply Wall St.
Will Teva’s (TEVA) Extended Sustainability-Linked Credit Line Reshape Its Balance Sheet and Risk Narrative?
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Has Teva’s 80% Surge in 2024 Already Priced In Its Turnaround Potential?
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
➖
AI Sentiment
Neutral
5/10
Morningstar Research
Analyst Report: Teva Pharmaceutical Industries Limited
📊
AI Sentiment
Positive
7/10
MT Newswires
Teva Pharmaceutical Industries Insider Sold Shares Worth $3,311,126, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
Compare TEVA vs Leading Stocks
See how TEVA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TEVA Teva Pharmaceutical Industries Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.